Cantor Fitzgerald Forecasts Immatics FY2026 Earnings

Immatics (NASDAQ:IMTX) – Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Immatics in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt expects that the company will post earnings of ($1.50) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Immatics’ current full-year earnings is ($0.72) per share.

Several other brokerages have also recently issued reports on IMTX. Wall Street Zen cut shares of Immatics from a “hold” rating to a “strong sell” rating in a report on Thursday, May 22nd. Deutsche Bank Aktiengesellschaft began coverage on Immatics in a research note on Wednesday, May 28th. They set a “buy” rating and a $10.00 target price on the stock. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $14.67.

Immatics Stock Performance

Shares of Immatics stock opened at $6.00 on Tuesday. The stock has a market capitalization of $729.30 million, a price-to-earnings ratio of -9.09 and a beta of 0.83. Immatics has a 52-week low of $3.30 and a 52-week high of $13.69. The company has a fifty day moving average of $4.72 and a 200-day moving average of $5.47.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04. The company had revenue of $20.12 million during the quarter, compared to the consensus estimate of $14.92 million. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Suvretta Capital Management LLC purchased a new position in shares of Immatics during the 4th quarter valued at $36,014,000. abrdn plc raised its position in shares of Immatics by 49.2% during the 4th quarter. abrdn plc now owns 347,379 shares of the company’s stock valued at $2,470,000 after buying an additional 114,479 shares in the last quarter. Guggenheim Capital LLC purchased a new position in shares of Immatics in the 4th quarter worth approximately $101,000. Northern Trust Corp raised its stake in shares of Immatics by 31.5% in the fourth quarter. Northern Trust Corp now owns 47,226 shares of the company’s stock valued at $336,000 after acquiring an additional 11,304 shares during the period. Finally, Millennium Management LLC raised its position in Immatics by 379.2% in the 4th quarter. Millennium Management LLC now owns 156,686 shares of the company’s stock worth $1,114,000 after purchasing an additional 123,986 shares during the period. Hedge funds and other institutional investors own 64.41% of the company’s stock.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.